KDE40101
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes., PMID:40514652
[Weight reduction with incretin mimetics-Opportunities and risks]., PMID:40514554
A Systemic Review of Pharmacological Management of Pediatric Obesity., PMID:40511007
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies., PMID:40507553
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?, PMID:40497353
Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide., PMID:40491599
Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics., PMID:40490304
Anti-CGRP monoclonal antibodies counteract establishment of food aversive memories and chemotherapy-induced anorexia and weight loss., PMID:40490094
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581
Systematic Review and Meta-Analysis of Liraglutide Treatment in Children Who Are Overweight or Obese: A Therapeutic Paradigm Shift?, PMID:40486450
Genetic and physiological insights into satiation variability predict responses to obesity treatment., PMID:40482646
The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis., PMID:40481408
Prior metabolic surgery attenuates the weight-loss efficacy of liraglutide in patients with mild obesity., PMID:40475994
Metabolic resilience: liraglutide's potential in alleviating depressive symptoms., PMID:40471368
Repurposing liraglutide to the management of DSS-induced colitis: a potential for promoting autophagy., PMID:40471244
Multicenter, Retrospective, observational study to evaluate the real-world use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in the Pakistani population with Type-2 diabetes (T2D)., PMID:40469149
GLP-1-based medications: Mechanisms involved in obesity treatment., PMID:40466247
The impact of obesity and weight loss treatment on metabolic parameters, cardiovascular autonomic and sensory nerve function and in vitro fertilization outcomes in infertile women: a pilot study., PMID:40463745
Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial., PMID:40463568
Exploring the Effect and Mechanism of Liraglutide in Treating Depression Based on Network Pharmacology and Experimental Analysis., PMID:40461955
Impact of the injectable weight-loss medications, glucagon-like peptide-1 receptor agonists, on reproductive health in non-polycystic ovary syndrome state., PMID:40459435
A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait., PMID:40458827
Liraglutide modulates cyclooxygenase and α7 acetylcholine receptors: in vitro and in silico insights into its anti-inflammatory role in LPS-induced inflammation in RAW 264.7 macrophages., PMID:40448826
Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis., PMID:40444045
A Validated, Stability-Indicating HPLC Method for the Simultaneous Determination of Five Related Substances in Liraglutide Drug Substance., PMID:40442972
Glucagon-Like Peptide-1 Use and Healthcare Resource Utilization for Depression and Anxiety Among Adults with Type 2 Diabetes: 2019 to 2023., PMID:40439835
GLP-1 receptor agonists and the risk for cancer: A meta-analysis of randomized controlled trials., PMID:40437949
Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta-Analysis., PMID:40437653
Liraglutide as a novel therapeutic for overweight in canines: A clinical study., PMID:40436366
The mechanism of liraglutide on promoting osteogenesis via macrophages polarization under the inflammatory and oxidative stress in osteoporosis., PMID:40436107
Efficacy and tolerance of liraglutide for weight loss in obese, type 2 diabetes and haemodialysis patients., PMID:40432380
Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer's Disease., PMID:40430434
Effects of Combination Treatment with Leptin and Liraglutide on Glucose Metabolism in Insulin-Dependent Diabetic Mice., PMID:40429740
Expression of Concern: Paladugu et al. Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. Int. J. Mol. Sci. 2021, 22, 860., PMID:40429612
Anti-Obesity Medications and the Risk of Obesity-Related Cancers in Older Women: A Propensity Score Matching Analysis of 2007-2015 SEER-Medicare Data., PMID:40427123
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE., PMID:40424051
Current and Emerging Parenteral and Peroral Medications for Weight Loss: A Narrative Review., PMID:40422561
Comparing the Efficacy of Liraglutide and Semaglutide on Weight Loss: Experience from the Middle East Gulf Region and Literature Review., PMID:40417637
Realisation of Remission of Diabetes Using Pharmacotherapy (DiaRem-1)., PMID:40416453
Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System., PMID:40413246
Heterogeneity in response to GLP-1 receptor agonists in type 2 diabetes in real-world clinical practice: insights from the DPV register - an IMI-SOPHIA study., PMID:40404820
Assessment of innate immune response modulating impurities (IIRMI) in synthetic peptide drugs (liraglutide)., PMID:40398094
Short-term effects of liraglutide and semaglutide on weight gain and adiposity by rats fed a Western diet., PMID:40389050
Comparison of the cardioprotective effects of liraglutide, dapagliflozin and their combination in a rat model of diabetes induced by streptozotocin., PMID:40389022
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial., PMID:40388190
Ex vivo lung perfusion with GLP-1R agonist mitigates ischemia/reperfusion injury through pyroptosis modulation in lung transplantation- an experimental study., PMID:40387728
Inference for Cumulative Incidences and Treatment Effects in Randomized Controlled Trials With Time-to-Event Outcomes Under ICH E9 (R1)., PMID:40386918
Efficacy of Liraglutide for Weight Loss in Overweight and Obese Non-diabetic Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials., PMID:40385831
Ameliorative effect of GLP1 agonist on vascular calcification in normoglycemic aged rat aorta via miR34a/SIRT6/NRF2/HO-1 signalling pathway., PMID:40383222
Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis., PMID:40382437
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
